Sign in

    Bill Plovanic

    Research Analyst at Canaccord Genuity - Global Capital Markets

    Bill Plovanic is Managing Director and Senior Equity Analyst at Canaccord Genuity - Global Capital Markets, specializing in U.S. medical technology coverage. He covers leading medtech companies such as DexCom, iRhythm Technologies, Edwards Lifesciences, Globus Medical, AngioDynamics, and TransMedics Group, holding a 42.62% success rate and an average return of 3.27 stars in analyst performance rankings. Plovanic began his equity research career over 20 years ago, with prior senior roles at First Albany Capital and operational leadership including President and CEO roles at Obalon Therapeutics before rejoining Canaccord in 2020. He holds a BS in finance from Bradley University, is a long-time CFA charterholder, and has been recognized as a Wall Street Journal 'All Star' Analyst and ranked #1 by Starmine for stock picking in medical technology.

    Bill Plovanic's questions to TANDEM DIABETES CARE (TNDM) leadership

    Bill Plovanic's questions to TANDEM DIABETES CARE (TNDM) leadership • Q2 2025

    Question

    In a follow-up, Bill Plovanic of Canaccord Genuity asked to quantify the contribution from pharmacy channel inventory build in Q2 and how much of that was anticipated.

    Answer

    EVP, CFO & Treasurer Leigh Vosseller quantified the benefit from initial stocking orders in the pharmacy channel as a 'few million dollars.' She indicated this was a driver in the quarter and explains the expected slight sequential step-down in U.S. revenue from Q2 to Q3, which is consistent with normal seasonality but amplified by this stocking dynamic.

    Ask Fintool Equity Research AI